Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Turning Point Therapeutics Inc.

www.tptherapeutics.com

Latest From Turning Point Therapeutics Inc.

IPO Update: Pace Of US Offerings Slows As 13 Biopharmas Go Public In 2019

With about three IPOs per month compared with a pace of nearly six per month in 2018, drug developers have raised $1.55bn with US offerings this year – though returns have been mixed.

Financing Business Strategies

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.

Financing Business Strategies

Finance Watch: Genfit Launches IPO To Expand US Presence Ahead Of Phase III NASH Results

Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.

Financing Business Strategies

Venture Funding Deals: Gotham Raises $54m To Advance Epitranscriptomics

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced September and October 2018.
Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • TP Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Turning Point Therapeutics Inc.
  • Senior Management
  • Athena M Countouriotis, MD, Pres. & CEO
    Yi Larson, EVP, CFO
    J. Jean Cui, PhD, CSO
  • Contact Info
  • Turning Point Therapeutics Inc.
    Phone: (858) 926-5251
    10628 Science Ctr. Dr.
    Ste. 225
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register